# Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

> **NCT02806986** · PHASE3 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 61 (actual)

## Conditions studied

- Primary Immunodeficiency

## Interventions

- **BIOLOGICAL:** IGSC 20%

## Key facts

- **NCT ID:** NCT02806986
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-05-15
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806986, "Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02806986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*